


Lexicon Pharmaceuticals, Inc. (LXRX)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001062822

Lexicon Pharmaceuticals, Inc. LXRX; healthcare	
Grade	D/E  on the D/E boundary of 371 graded peers percentile 81.1; sampling error 2.5 points; lower is stronger
Rank	301 of 371
Profitability	D  percentile 71.6
Solvency	C  percentile 52.7
Growth and financing	C  percentile 56.1
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$120M to \$591M assets total assets \$185.0M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active; fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 5, 2026 218 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	\$1.75 2026-10-08; market equity \$780.9M
Price used in grade	None



D/E, the sloth
on the D/E boundary of its sector; letters are fifths of the 371 graded peers


Share price, twelve months to the rescan
split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: E from Mar 21, 2019, E from Apr 21, 2024, D from Aug 21, 2026, D/E from Sep 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 5, 2026

We are a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. We are devoting most of our resources to the research and development of our most advanced drug candidates and the commercialization of our approved drug, INPEFA® (sotagliflozin). We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for hypertrophic cardiomyopathy, or HCM, and are conducting the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. We are separately pursuing regulatory approval of ZYNQUISTA® (sotagliflozin) as a treatment for type 1 diabetes. The

U.S.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 71.6						
Gross profitability		26.8%	32.2%	53.4	372	2025-12-31
Return on invested capital		not computable	9.3%			latest aligned inputs end 2016-12-31; latest annual assets end 2025-12-31
Accruals ratio		7.2%	(6.6%)	89.8	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			annual revenue must exceed \$100,000
Solvency, sleeve percentile 52.7						
Twelve-month failure probability		0.05%	0.07%	38.1	248	2026-06-30
Altman Z double-prime		(33.00)	(0.31)	82.1	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31
Current ratio		4.88x	2.96x	37.8	839	2025-12-31
Growth and financing, sleeve percentile 56.1						
Revenue growth, three-year compound		not computable	10.0%			current value must be positive and the base must exceed \$100,000
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		(1.6%)	2.1%	54.8	704	2025-12-31
Net share issuance, one year		17.2%	2.5%	57.3	634	2026-03-04


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 40,921,000 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
296	Ironwood Pharmaceuticals Inc. (IRWD)	79.7	D/E	late filer, fortress balance sheet
297	Champions Oncology, Inc. (CSBR)	80.0	D/E	
298	Voyager Therapeutics, Inc. (VYGR)	80.3	D/E	short runway
299	Lucid Diagnostics Inc. (LUCD)	80.5	D/E	dilution
300	Merck & Co., Inc. (MRK)	80.8	D/E	
301	Lexicon Pharmaceuticals, Inc. (LXRX) <	81.1	D/E	fortress balance sheet
302	Hyperfine, Inc. (HYPR)	81.4	D/E	
303	Surgery Partners, Inc. (SGRY)	81.6	D/E	late filer
304	Personalis, Inc. (PSNL)	81.9	D/E	
305	Accuray Inc. (ARRAY)	82.2	D/E	late filer
306	Moderna, Inc. (MRNA)	82.4	D/E	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	66.7%	8.0%	82
Distance from 52-week high	(33.3%)	(31.4%)	46
EBIT to enterprise value	(5.8%)	(1.5%)	40
Free cash flow yield	(8.7%)	(1.0%)	34
Book value to price	0.22	0.28	43
Sales to price	0.06	0.31	19
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	0.30	(0.14)	82

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 4 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$40.9M
Operating cash flow, four quarters	-\$65.0M
Months of runway	7.6

Days since last periodic filing

64 (10-Q received Aug 6, 2026)

Median daily dollar volume, 63 sessions

\$5.8M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:Revenues	\$49.8M	2025-12-31	2026-03-05	10-K	0001062822-26-000050
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$274,000	2025-12-31	2026-03-05	10-K	0001062822-26-000050
3	assets	us-gaap:Assets	\$185.0M	2025-12-31	2026-03-05	10-K	0001062822-26-000050
4	operating income	us-gaap:OperatingIncomeLoss	-\$127.2M	2016-12-31	2019-03-15	10-K	0001062822-19-000007
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItemsAndNoncontrollingInterests	\$11.4M	2016-12-31	2019-03-15	10-K	0001062822-19-000007
6	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2016-12-31	2018-03-01	10-K	0001062822-18-000008
7	total debt	us-gaap:LongTermDebt	\$101.4M	2016-12-31	2017-03-06	10-K	0001062822-17-000013
8	book equity	us-gaap:StockholdersEquity	\$167.5M	2016-12-31	2020-03-12	10-K	0001062822-20-000015
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$46.6M	2016-12-31	2020-03-12	10-K	0001062822-20-000015
10	total debt	us-gaap:LongTermDebt	\$105.8M	2015-12-31	2016-03-11	10-K	0001062822-16-000051
11	book equity	us-gaap:StockholdersEquity	\$286.0M	2015-12-31	2019-03-15	10-K	0001062822-19-000007
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$203.0M	2015-12-31	2019-03-15	10-K	0001062822-19-000007
13	net income	us-gaap:NetIncomeLoss	-\$50.3M	2025-12-31	2026-03-05	10-K	0001062822-26-000050
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$67.9M	2025-12-31	2026-03-05	10-K	0001062822-26-000050
15	assets	us-gaap:Assets	\$298.4M	2024-12-31	2026-03-05	10-K	0001062822-26-000050
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$6.0M	2024-12-31	2025-03-07	10-K	0001062822-25-000013
17	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$616,000	2024-12-31	2026-03-05	10-K	0001062822-26-000050
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.1M	2023-12-31	2025-03-07	10-K	0001062822-25-000013
19	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$85,000	2023-12-31	2026-03-05	10-K	0001062822-26-000050
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$0	2022-12-31	2025-03-07	10-K	0001062822-25-000013
21	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$0	2022-12-31	2025-03-07	10-K	0001062822-25-000013
22	current assets	us-gaap:AssetsCurrent	\$101.9M	2025-12-31	2026-03-05	10-K	0001062822-26-000050
23	current liabilities	us-gaap:LiabilitiesCurrent	\$20.9M	2025-12-31	2026-03-05	10-K	0001062822-26-000050
24	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$2.0B	2025-12-31	2026-03-05	10-K	0001062822-26-000050
25	operating income	us-gaap:OperatingIncomeLoss	-\$48.9M	2025-12-31	2026-03-05	10-K	0001062822-26-000050
26	book equity	us-gaap:StockholdersEquity	\$107.5M	2025-12-31	2026-03-05	10-K	0001062822-26-000050
27	liabilities	us-gaap:Liabilities	\$77.4M	2025-12-31	2026-03-05	10-K	0001062822-26-000050
28	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	\$5.4M	2022-12-31	2023-03-03	10-K	0001062822-23-000007
29	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$46.3M	2022-12-31	2024-03-25	10-K	0001062822-24-000008
30	operating income	us-gaap:OperatingIncomeLoss	-\$100.8M	2022-12-31	2025-03-07	10-K	0001062822-25-000013
31	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$427,000	2022-12-31	2025-03-07	10-K	0001062822-25-000013
32	interest expense	us-gaap:InterestExpense	\$2.8M	2022-12-31	2023-03-03	10-K	0001062822-23-000007
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$0	2025-12-31	2026-03-05	10-K	0001062822-26-000050
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$178.8M	2024-12-31	2026-03-05	10-K	0001062822-26-000050
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.0M	2024-12-31	2026-03-05	10-K	0001062822-26-000050
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$161.9M	2023-12-31	2026-03-05	10-K	0001062822-26-000050
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$470,000	2023-12-31	2026-03-05	10-K	0001062822-26-000050
38	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$88.9M	2022-12-31	2025-03-07	10-K	0001062822-25-000013
39	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.3M	2022-12-31	2025-03-07	10-K	0001062822-25-000013
40	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$231,000	2016-12-31	2019-03-15	10-K	0001062822-19-000007
41	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$2.1M	2016-12-31	2019-03-15	10-K	0001062822-19-000007
42	current assets	us-gaap:AssetsCurrent	\$357.9M	2016-12-31	2018-03-01	10-K	0001062822-18-000008
43	current liabilities	us-gaap:LiabilitiesCurrent	\$164.6M	2016-12-31	2018-03-01	10-K	0001062822-18-000008
44	current assets	us-gaap:AssetsCurrent	\$532.4M	2015-12-31	2017-03-06	10-K	0001062822-17-000013
45	current liabilities	us-gaap:LiabilitiesCurrent	\$123.0M	2015-12-31	2017-03-06	10-K	0001062822-17-000013
46	assets	us-gaap:Assets	\$229.4M	2023-12-31	2025-03-07	10-K	0001062822-25-000013
47	assets	us-gaap:Assets	\$194.3M	2022-12-31	2024-03-25	10-K	0001062822-24-000008
48	shares outstanding	dei:EntityCommonStockSharesOutstanding	423,680,611	2026-03-04	2026-03-05	10-K	0001062822-26-000050
49	shares outstanding	dei:EntityCommonStockSharesOutstanding	361,492,295	2025-02-28	2025-03-07	10-K	0001062822-25-000013